

A PLUS SYNDICATED

SMMML newsletter


March 2023

Based on data from January & February 2023

Monthly updates around multiple myeloma



Confidential



The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.

◆ Who will benefit from this newsletter?



Any professionals interested in keeping up with developments around multiple myeloma:

- Marketers
- Business Analysts
- But also HCPs who want to anticipate the future landscape of MM management



Introduction on Multiple Myeloma

What is Multiple Myeloma?



70
YEARS



■ 5 year survival rate ~50%



Read more on Multiple Myeloma:



→ [Professional version in English](#)



→ [Professional version in French](#)



→ [Consumer version in English](#)

→ [Consumer version in French](#)

MM lines of therapy based on to the following definitions



1st line Induction prior SCT

For stem cell candidates, the first step to gain a response to reduce the tumor burden before SCT. Please note that patients who received more than one SCT are considered to be in “1st line prior to stem cell transplant” for the latest SCT procedure planned. For instance, should a patient receive an induction treatment prior to a 2nd SCT, he should be considered as a 1st line transplant patient.


1st line Consolidation post SCT

1st line therapy **after** stem cell transplant to **deepen the response** achieved by adding a **short course** of full dose therapy.

1st line Maintenance post SCT


1st line therapy **after** stem cell transplant to **sustain the quality of the response** achieved by adding a long course – from several months up to disease progression – of reduced dose therapy.

Drugs approved by European Medicines Agency (EMA)



Brand name	Active substance	Manufacturer	Class of therapy	EMA Date of authorisation	Line of treatment	Product Monograph
Revlimid®	lenalidomide	BMS	Immunomodulating agents (IMiDs)	14/06/2007	All lines	Click here
Thalidomide BMS® / Thalomid® (US)	thalidomide	BMS	Immunomodulating agents (IMiDs)	16/04/2008	All lines	Click here
Imnovid® / Pomalyst® (US)	pomalidomide	BMS	Immunomodulating agents (IMiDs)	05/08/2013	2L+ (after Revlimid and Velcade)	Click here
Pepaxti® / Pepaxto® (US)	melflufen	Oncopeptides AB	Peptide conjugated alkylator	17/08/2022	Triple class exposed / 3L+ / 4L+ / 5L+	Click here
Velcade®	bortezomib	Janssen	Proteasome inhibitors (PIs)	26/04/2004	1LSC / 1LNSCT	Click here
Kyprolis®	carfilzomib	Amgen	Proteasome inhibitors (PIs)	19/11/2015	2L+ / 3L+	Click here
Ninlaro®	ixazomib	Takeda	Proteasome inhibitors (PIs)	21/11/2016	2L+	Click here
Farydak®	panobinostat	Novartis + (Secura Bio)	Histone deacetylase inhibitors (HDACis)	28/08/2015	2L+ Relapsed / Refractory	Click here
Darzalex®	daratumumab	Janssen	Monoclonal antibody against CD38 (Mabs)	20/05/2016	All lines	Click here
Empliciti®	elotuzumab	BMS + (AbbVie)	Monoclonal antibody against SLAMF7 (Mabs)	11/05/2016	2L+ / 3L+	Click here
Sarclisa®	isatuximab	Sanofi	Monoclonal antibody against CD38 (Mabs)	30/05/2020	2L+ / 3L+	Click here
Tecvayli®	teclistamab	Janssen	BiTE	21/07/2022	2L+ / 3L+	Click here
Blenrep® / Belamaf® (US)	belantamab mafodotin-blmf	GSK	Antibody-drug conjugates (BCMA)	25/08/2020	2L+ (4L+ after P, IMiD and MAB (L5+ in Italy))	Click here
Nexpovio® / Xpovio® (US)	selinexor	Karyopharm Therapeutics	Nuclear export inhibitor (SINE)	26/03/2021	Penta-refractory (2xPI + 2xIMiDs + 1 Mab)	Click here
Venclyxto® / Venclexta® (US)	venetoclax	AbbVie	B-cell lymphoma 2 (BCL-2)	04/12/2016	2L+ (already used in CLL / AML treatments)	Click here
Abecma®	idecabtagene vicleucel	BMS	Cell-based gene therapy (CAR-T)	18/08/2021	Triple class exposed / 3L+ / 4L+ / 5L+	Click here
Carvykti®	ciltacabtagene autoleucel	Janssen	Cell-based gene therapy (CAR-T)	25/05/2022	L3 / L4+ / L5+	Click here
Aredia®	pamidronate	Novartis	Bisphosphonates for bone disease	31/10/1991	Supportive care / Long-term use (5+ years)	Click here
Zometa®	zoledronate	Novartis	Bisphosphonates for bone disease	20/03/2001	Supportive care / Long-term use (5+ years)	Click here
Prolia® + Xgeva®	denosumab	Amgen	Bisphosphonates for bone disease	26/05/2010 - 13/07/2011	Supportive care	Prolia® / Xgeva®
Mozobil®	plerixafor	Genzyme	Stem cell mobilazor	30/07/2009	Supportive care	Click here

MM treatment history timeline



- IMiDs
- PIs
- IMS
- Mabs
- HDACi
- SINE
- BCMA
- CAR-T

1844
"Rhubarb & orange peel, strengthening plaster to the chest, a pound of blood removed & leeches applied for maintenance therapy".

1947
 Urethane

1958
 Melphalan

1962
 Corticosteroids

1983
 Autologous transplantation

1984
 Vincristine + Adriamycin + Dexamethasone

2013
 pomalidomide (Imnovid®/Pomalyst®)

2012
 carfilzomib (Kyprolis® US)

2010
 bendamustine (Levact®)

2005
 lenalidomide (Revlimid®)

2002
 bortezomib (Velcade®)

1999
 thalidomide

2015
 panabinostat (Farydak®)

2016
 elotuzumab (Empliciti®)
 daratumumab (Darzalex®)
 ixazomib (Ninlaro®)


2020
 belantamab mafodotin (Blenrep® EU, Belamaf® US)

2021
 selinexor (Nexpovio® EU, Xpovio® US)
 isatuximab (Sarclisa®)
 idecabtagene vicleucel (Abecma®)

2022
 melflufen (Pepaxti® EU, Pepaxto® US)
 ciltacabtagene autoleucel (Carvykti®)

20??
 teclistamab (Tecvayli®) ★
 marizomib, anetumab, ravtansine, venetoclax, oprozomib, talquetamab, elranatamab

Confidential



16+
YEARS

17+
COUNTRIES OVER TIME

UP
TO **90**
HCPs
per wave
per country

UP
TO **4**
WAVES
per year

4,5k
PATIENTS CHARTS
per wave

18k
PATIENTS CHARTS
per year (in EU5)

What's new **MMsyndiTrack™**

Launching of a US pilot wave, Why ?


- Needs from clients for MM US data
- Back data for EU5 for 15 years
- MM US market changing fast
- Different needs in the US market for labs (patients' ethnicity treatments gap as an example)

APLUSA's added value

- Quarterly + month to month data collection (our competitors → only quarterly data)
- Market adaptability: adjusting our questionnaires and updating the list of treatments by including market trends on a monthly basis → **new CAR-Ts + BisAbs**
- Patient's full treatment history
- Deliverables with Power BI DID



January/February 2023



● CONTENTS

01.

News around clinical trials in phase II

- Phase II relapse/refractory : CAR-T (January)
- Phase II relapse/refractory : Bispecific therapies (January)
- Phase II Relapse/Refractory Bispecific Therapies (February)

02.

News around clinical trials in Phase III

- Phase III relapse/refractory : CAR-T (January)
- Phase III relapse/refractory : maintenance therapy (January)
- Phase II Relapse/Refractory CAR-T (February)

03.

Themes of discussion : HCPs

- SOV Themes of discussion
- Posts driving most engagement

04.


News articles overtime

- Volume of articles per volume of mentions
- Articles per themes

05.

Drug approvals

- Drug market watch



● SCOPE



The scope of the analysis is focused on mentions coming **worldwide**.*



There were a total of **49K** mentions from patients recorded during the listening period from **January 1st, 2023**, to **February 28th, 2023**.




A majority of mentions came from **News (43%), Twitter (39%), Instagram (12%), Forums (2%), Reddit (2%), Tumblr (1%)** and **blogs (1%)**.



A total of **12K** unique authors were identified.

: Myeloma OR multiplemyeloma OR #Mmsm OR #Myeloma OR #Curemyeloma* OR #Mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)

Methodology



Drugs in clinical trials (Phase II) monitored during the listening period



Molecule name	Commercial name	Class	Manufacturer	Trial names + link (ctrl + right click) / line of treatment / Combination being studied
lenalidomide	Revlimid®	immunomodulatory drugs (IMiDs)	BMS	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone MASTER (???): dexamethasone, lenalidomide, daratumumab, carfilzomib
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone
Bortezomib	Velcade®	Proteasome inhibitors	Takeda	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib)
carfilzomib	Kyprolis®	Proteasome inhibitor	Amgen	FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone MASTER (???): dexamethasone, lenalidomide, daratumumab, carfilzomib Cardamon (???): cyclophosphamide, dexamethasone, carfilzomib
daratumumab	Darzalex®	Monoclonal antibody anti-CD38	Janssen	GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd) FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone REBUILD (RR): Monotherapy NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) MASTER (???): dexamethasone, lenalidomide, daratumumab, carfilzomib
elotuzumab	Empliciti®	Monoclonal antibody SLAMF7	BMS/AbbVie	ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone
isatuximab	Sarclisa®	Monoclonal antibody anti-CD38	Sanofi	NCT05123131 (ND): isatuximab, bortezomib, lenalidomide, dexamethasone NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone
belantamab mafodotin, (GSK2857916)	Blenrep®	Antibody drug–conjugate (ADC)	GSK	DREAMM-2 (RR): Monotherapy
Ciltacabtagene (cilta cel, JNJ 68284528, LCAR B38M)	Carvykti®	CAR T-Cell Therapy Anti-BCMA	Janssen	CARTIFAN-1 (RR): Monotherapy CARTITUDE (RR): Monotherapy CARTITUDE 2 (RR): Monotherapy
idecabtagene vicleucel (ide cel)	Abecma	CAR T-Cell Therapy Anti-BCMA	BMS	KarMMa-2 (RR): Monotherapy (one arm with lenalidomide)
Zevorcabtagene autoleucel (zevor cel)	N/A	CAR T-Cell Therapy Anti-BCMA	CARsgen Therapeutics	LUMMICAR-2 (RR): Monotherapy
C-CAR088	N/A	CAR T-Cell Therapy Anti-BCMA	Cellular Biomedicine	NCT05521802 (RR): Monotherapy
teclistamab	Tecvayli®	Bispecific Antibody anti-BCMA	Janssen	MajesTEC-1 : (RR): Monotherapy
talquetamab	N/A	Bispecific antibody T-cell redirecting	Janssen	MonumentAL-1 (RR): Monotherapy
elranatamab (PF-06863135)	N/A	Bispecific Antibody anti-BCMA x Anti-CD3	Pfizer	MagneticMM-9 (RR): Monotherapy

Phase II Relapse/Refractory CAR-T: Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China



Headlines/Hot off the press

“ Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China ”

“Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China’s National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for ciltacabtagene autoleucel (cilta-cel).” Click [here](#) to read the full article

Sponsor & collaborator



CARTIFAN-1

Ctrl + click to access clinical trial: [NCT03758417](#)

“A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma”



Molecule


Ciltacabtagene autoleucel



Phase II Relapse/Refractory Bispecific therapies: Janssen submits marketing application for talquetamab



Clinical trial mentioned/Sponsor



MonumentAL-1
Ctrl + click to access clinical trial: [NCT04634552](https://clinicaltrials.gov/ct2/show/study/NCT04634552)

"The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)."

MajesTEC-1
Ctrl + click to access clinical trial: [NCT04557098](https://clinicaltrials.gov/ct2/show/study/NCT04557098)

"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)"

Headlines/Hot off the press

Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma

"Ajai Chari, MD, shares some background on talquetamab, reported safety and efficacy findings from MonumentAL-1, and highlighted other ways in which the agent is being explored in multiple myeloma." Click [here](#) to read the full article

Janssen submits marketing application for talquetamab

"European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma" Click [here](#) to read the full article

Teclistamab Combination Shows Higher Response Rate in Multiple Myeloma

"Emma Searle, PhD, discusses results of the MajesTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition. Click [here](#) to read the full article

Molecules

Talquetamab


Teclistamab



Phase II Relapse/Refractory Bispecific Therapies: FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma



Clinical trial mentioned/Sponsor



Headlines/Hot off the press

“ FDA Grants Priority Review to Elranatamab in Relapsed/Refractory Myeloma ”

“The FDA has granted a priority review to the biologics license application for elranatamab for the treatment of patients with relapsed/refractory multiple myeloma.” Click [here](#) to read the full article

“ Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma ”

“Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.” Click [here](#) to read the full article

“ MonumenTAL-1 trial Shows Promise With Talquetamab in R/R Myeloma ”

Sikander Ailawadhi, MD, discussed the safety and efficacy of talquetamab in heavily pretreated patients with relapsed/refractory multiple myeloma following a readout of the phase 1/2 MonumenTAL-1 trial. Click [here](#) to read the full article

MagnetisMM-3

Ctrl + click to access clinical trial: [NCT04649359](#)

“Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb”

Molecules

Elranatamab

MajesTEC-1

Ctrl + click to access clinical trial: [NCT04557098](#)

“A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)”

Teclistamab

MonumenTAL-1

Ctrl + click to access clinical trial: [NCT04634552](#)

“The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).”

Talquetamab

II first-in-human efficacy and safety
BCMA bispecific
 Priority Review is intended to direct marketing authorization application
refractory multiple myeloma
 CD3-targeted bispecific antibody
 treatment of patients with relapsed
 Application for talquetamab to the FDA
Medicines Agency
 Biologics License Application for elranatamab data from the Phase

Fading Trending

Drugs in clinical trials (Phase III) monitored during the listening period



Molecule name	Commercial name	Class	Manufacturer	Trial names + link (ctrl + right click) / line of treatment / Combination being studied
lenalidomide	Revlimid®	immunomodulatory drugs (IMiDs)	BMS	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone ATLAS (Maintenance): Lenalidomide, Carfilzomib, Dexamethasone DRAMMATIC (??): Lenalidomide, Daratumumab EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone TOURMALINE (RR): Ixazomib Plus Lenalidomide and Dexamethasone Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib AURIGA (Maintenance): Daratumumab Plus Lenalidomide
pomalidomide	Imnovid® / Pomalyst® (US)	immunomodulatory drugs (IMiDs)	BMS	ICARIA-MM (RR): Isatuximab, Pomalidomide, Dexamethasone
bortezomib	Velcade®	Proteasome inhibitors (PIs)	Takeda	DETERMINATION (RR): lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) BOSTON (RR): selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone CASTOR (RR): Daratumumab, Bortezomib and Dexamethasone Bellini (RR): venetoclax plus bortezomib and dexamethasone DREAMM 7 (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone
carfilzomib	Kyprolis®	Proteasome inhibitors (PIs)	Amgen	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ATLAS (Maintenance): Carfilzomib, Lenalidomide, Dexamethasone Myeloma XI (ND): cyclophosphamide, dexamethasone plus lenalidomide with or without carfilzomib
ixazomib	Ninlaro®	Proteasome inhibitors (PIs)	Takeda	OPTIMUM (RR): Ixazomib, Lenalidomide TOURMALINE (RR): Ixazomib Plus Lenalidomide and Dexamethasone
Bb2121, Idecabtagene vicleucel	Abecma®	CAR T-cell therapy	BMS	KarMMa-3 (RR): Monotherapy
ciltacabtagene	Carvykti®	CAR T-cell therapy BCMA-directed	Janssen	CARTITUDE-4 (RR): Monotherapy
daratumumab	Darzalex®	Monoclonal antibody anti-CD38	Janssen	MajesTEC-3 : (RR): Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) MAIA (ND): daratumumab in combination with lenalidomide and dexamethasone DRAMMATIC (??): Lenalidomide, Daratumumab EQUATE (ND): daratumumab, bortezomib, lenalidomide and dexamethasone CASTOR : (RR): Daratumumab, Bortezomib and Dexamethasone POLLUX (RR): Daratumumab, Lenalidomide, and Dexamethasone MagnetisMM-5 (RR): Monotherapy or doublet therapy with daratumumab AURIGA (Maintenance): Daratumumab Plus Lenalidomide
isatuximab	Sarclisa®	Monoclonal antibody anti-CD38	Sanofi	IKEMA (RR): Isatuximab, Carfilzomib And Dexamethasone ICARIA-MM (RR): Isatuximab, Pomalidomide, and Dexamethasone
belantamab mafodotin-blmf	Blenrep® / Belamaf® (US)	Antibody-drug conjugates (BCMA)	GSK	DREAMM-3 (RR): Monotherapy DREAMM 7 (RR): Belantamab Mafodotin, Bortezomib and Dexamethasone DREAMM 8 (RR): Belantamab Mafodotin Plus Pomalidomide and Dexamethasone

Phase III Relapse/Refractory CAR-T: Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma



Headlines/Hot off the press

“ **Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma** ”

“The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis..” Click [here](#) to read the full article

Sponsor



CARTITUDE-4
Ctrl + click to access clinical trial: [NCT04181827](#)

“A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma”

Molecule

Ciltacabtagene autoleucel



Phase III R/R CAR-T N= 180 mentions
Social media listening period: January 2023
Scope: worldwide in English

Phase III Relapse/Refractory Maintenance triplet: Triple Drug Combo Beats Single Therapy in Multiple Myeloma Maintenance



Headlines/Hot off the press

“ Triple Drug Combo Beats Single Therapy in Multiple Myeloma Maintenance ”

“New evidence supports the use of a three drug combo—carfilzomib, lenalidomide, and dexamethasone (KRd), for maintenance therapy after autologous stem cell transplantation in patients newly diagnosed with multiple myeloma. Maintenance therapy using these three drugs may improve progression-free survival as compared to single agent lenalidomide treatment.” Click [here](#) to read the full article

Sponsor

THE UNIVERSITY OF
CHICAGO

ATLAS
Ctrl + click to access clinical trial: [NCT02659293](#)

“Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma”

Combinations

carfilzomib + lenalidomide + dexamethasone



Phase II Relapse/Refractory CAR-T: Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMA-3 Study



Headlines/Hot off the press

“ **Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMA-3 Study** ”

“Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced the first publication and presentation of positive results from KarMMA-3” Click [here](#) to read the full article

Sponsor



KarMMA-3

Ctrl + click to access the clinical trial: [NCT03651128](#)



“Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMA-3)”


Molecule



idecabtagene vicleucel

CAR-T therapies were a focus of online conversations this month as the 5th European CAR-T cell meeting took place from the 9th to the 11th of February in Rotterdam, Netherlands. For more info see this [link](#).



 HCPs conversation N= 1528 mentions
 Social media listening period: February 2023
 Scope: worldwide in English

In terms of engagement, the iStopMM continues to generate interest as a tweet from Sigurdur Kristinsson, one of the lead of this trial, is the most retweeted.

Other tweets of interest included one from Dr Goodman announcing a new podcast whose aim is to share knowledge about treatment option in MM.

Dr Shah posted a tweet thanking the ASH organization for shedding spotlight on a study focused on nutrition.

Most engagement

Most retweeted, liked and replied to (Ctrl + right click to access tweets)



Sigurdur Kristinsson
@sykristinsson

The first study on the prevalence of smoldering myeloma just published in @NatureMedicine!

Full link: rdcu.be/c4026

We found the prevalence of SMM to be 0.5% in people >40 years
[Traduire le Tweet](#)



Aaron Goodman - "Papa Heme"
@AaronGoodman33

My new podcast. Brief and concise approaches to all things hematology. See how I handle newly diagnosed multiple myeloma.

[Traduire le Tweet](#)



Urvi Shah
@UrviShahMD

Thank you @ASH_hematology for recognizing our #mmsm nutrition research #ASHScholarAward @MSKHemOncTrials @MSKCancerCenter This wouldn't be possible without the support of @DrMvandenBrink @LesokhinMD @szusmani @adsouza_md @Neil_Iyengar @JunMaoMD @GiraltSergio & our research team

Top 5 influencers

1.



Vincent Rajkumar
[@VincentRK](#)

76,1 K followers

2.



Samer Al Hadidi
[@HadidiSamer](#)

2,7 K followers

3.



Saad Z. Usmani
[@szusmani](#)

8,8 K followers

4.



Noopur Raje
[@NoopurRajeMD](#)

8,6 K followers


5.




Al-Ola A Abdallah
[@Abdallah81MD](#)

2,7 K followers

Media: volume and articles per peak



Volume of articles overtime



A “NHS spending watchdog approves three-drug treatment which lets blood cancer patients live longer - potentially helping 6,000 Britons with multiple myeloma a year” [Link](#)

“Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma” [Link](#)

“Body Mass Index Tied to Multiple Myeloma Survival” [Link](#)

“Takeda’s **Ninlaro (ixazomib)** Receives **NICE Recommendation** for the Treatment of Multiple Myeloma” [Link](#)

B “Janssen Announces Unblinding of Phase 3 **CARTITUDE-4 Study of CARVYKTI® (cilta-cel)** as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma” [Link](#)

C “Alternative To Lenalidomide ID’d For Maintenance In Multiple Myeloma” [Link](#)

D “Karyopharm and Menarini Receive Full Marketing Authorization from the UK MHRA for **NEXPOVIO (selinexor)** in Combination with **Bortezomib and Dexamethasone** for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy” [Link](#)

E “Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma” [Link](#)

F “Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma” [Link](#)

G “**CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS** ANNOUNCE **CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339** IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA” [Link](#)

“Janssen Submits Marketing Authorisation Application to the **European Medicines Agency** Seeking Approval of **Talquetamab** for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma” [Link](#)





Approvals & recommendations

“NHS spending watchdog **approves three-drug treatment** which lets blood cancer patients live longer – potentially helping 6,000 Britons with multiple myeloma a year” [Link](#)

“Takeda’s **Ninlaro (ixazomib)** Receives **NICE Recommendation** for the Treatment of Multiple Myeloma” [Link](#)

“**Karyopharm** and **Menarini** Receive Full **Marketing Authorization** from the UK MHRA for **NEXPOVIO (selinexor) in Combination with Bortezomib and Dexamethasone** for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy” [Link](#)

“**Janssen** Submits **Marketing Authorisation** Application to the **European Medicines Agency** Seeking Approval of **Talquetamab** for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma” [Link](#)

CAR T-cell therapy

“**Janssen** Announces Unblinding of Phase 3 **CARTITUDE-4 Study of CARVYKTI®** (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma” [Link](#)

“Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma” [Link](#)

“Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FastCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma” [Link](#)

Misc.

“Inflammatory-Nutritional Score Helps Predict Survival in New Multiple Myeloma” [Link](#)

“Body Mass Index Tied to Multiple Myeloma Survival” [Link](#)

Maintenance therapy.

“**Alternative To Lenalidomide** ID’d For Maintenance In Multiple Myeloma” [Link](#)

VCP/p97 inhibitors

“**CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS** ANNOUNCE **CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339** IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA” [LINK](#)

Drug Market Watch

January – February 2023



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

“ Janssen Submits Marketing Authorisation Application to the European Medicines Agency ”

Seeking Approval of **Talquetamab** for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Link](#)



国家药品监督管理局
National Medical Products Administration


“ Legend Biotech Announces Acceptance of Its New Drug Application for **Ciltacabtagene Autoleucel (Cilta-Cel)** in China ”

“Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that China’s National Medical Products Administration (NMPA) has formally accepted its New Drug Application (NDA) for **ciltacabtagene autoleucel (cilta-cel)**.” [LINK](#)



“ **Elranatamab** wins FDA’s priority review for hard-to-treat myeloma ”

The U.S. Food and Drug Administration (FDA) has granted priority review to Pfizer’s application of its investigational under-the-skin therapy **elranatamab** for people with relapsed or refractory multiple myeloma. [Link](#)



NICE

National Institute for Health and Care Excellence

“ NICE recommends triplet regimen for relapsed multiple myeloma ”

NICE has recommended **Ninlaro** (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy. [Link](#)



Medicines & Healthcare products Regulatory Agency

“ MHRA Approves **Selinexor Plus Bortezomib/Dexamethasone** for Multiple Myeloma Following 1 Prior Therapy ”

The **United Kingdom’s** Medicines and Healthcare Products Regulatory Agency has granted full marketing authorization for **selinexor** in combination with bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy. [Link](#)